Ironwood Q3 revenue down 19% YoY to $91.6M; LINZESS Rx demand +13%

IRONWOOD PHARMACEUTICALS INC

2024-Q3 EPS reported -$0.01 revenue$260,865,000

GAAP net income $3.6M ($0.02 diluted EPS) vs $15.3M ($0.10) a year ago.
Total revenue $91.6M, down from $113.7M in Q3 2023; cites pricing headwinds.
LINZESS new-to-brand and extended-unit prescriptions each grew 13% YoY.
Apraglutide NDA submission for short bowel syndrome on track for Q1 2025.
Full-year 2024 financial guidance reaffirmed; Adjusted EBITDA $26.2M vs $49.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.